Literature DB >> 31013472

Is DNA a better assay for residual disease in chronic myeloid leukemia?

Jerald Radich1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 31013472      PMCID： PMC6269307          DOI： 10.3324/haematol.2018.205583

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

Review 1.  The "strong" RNA world hypothesis: fifty years old.

Authors:  Marc Neveu; Hyo-Joong Kim; Steven A Benner
Journal:  Astrobiology       Date:  2013-04-03       Impact factor: 4.335

2.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

3.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

4.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.

Authors:  R E Clark; I A Dodi; S C Hill; J R Lill; G Aubert; A R Macintyre; J Rojas; A Bourdon; P L Bonner; L Wang; S E Christmas; P J Travers; C S Creaser; R C Rees; J A Madrigal
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

5.  Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

Authors:  Xuelin Huang; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2012-01-31       Impact factor: 6.860

6.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

Review 7.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

8.  Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.

Authors:  David Wu; Ryan O Emerson; Anna Sherwood; Mignon L Loh; Anne Angiolillo; Bryan Howie; Jennifer Vogt; Mark Rieder; Ilan Kirsch; Christopher Carlson; David Williamson; Brent L Wood; Harlan Robins
Journal:  Clin Cancer Res       Date:  2014-06-26       Impact factor: 12.531

9.  Massively parallel digital transcriptional profiling of single cells.

Authors:  Grace X Y Zheng; Jessica M Terry; Phillip Belgrader; Paul Ryvkin; Zachary W Bent; Ryan Wilson; Solongo B Ziraldo; Tobias D Wheeler; Geoff P McDermott; Junjie Zhu; Mark T Gregory; Joe Shuga; Luz Montesclaros; Jason G Underwood; Donald A Masquelier; Stefanie Y Nishimura; Michael Schnall-Levin; Paul W Wyatt; Christopher M Hindson; Rajiv Bharadwaj; Alexander Wong; Kevin D Ness; Lan W Beppu; H Joachim Deeg; Christopher McFarland; Keith R Loeb; William J Valente; Nolan G Ericson; Emily A Stevens; Jerald P Radich; Tarjei S Mikkelsen; Benjamin J Hindson; Jason H Bielas
Journal:  Nat Commun       Date:  2017-01-16       Impact factor: 14.919

10.  BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.

Authors:  Ilaria S Pagani; Phuong Dang; Ivar O Kommers; Jarrad M Goyne; Mario Nicola; Verity A Saunders; Jodi Braley; Deborah L White; David T Yeung; Susan Branford; Timothy P Hughes; David M Ross
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941
View more
  1 in total

Review 1.  Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances.

Authors:  Cosimo Cumbo; Luisa Anelli; Giorgina Specchia; Francesco Albano
Journal:  Cancer Manag Res       Date:  2020-05-06       Impact factor: 3.989
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.